Treatment of Lung Cancer with Orally Administered Chinese Herbal Medicine: An Evidence Map between 1970-2020.
10.1007/s11655-022-3465-3
- Author:
Yue-Rong GUI
1
;
Ying ZHANG
1
;
Xue-Qian WANG
1
;
Bing-Jie FAN
1
;
Jing-Lei LI
1
;
Lan-Xin ZHANG
1
;
Fen FAN
1
;
Kang-di CAO
1
;
Xiao-Gang ZHANG
1
;
Wei HOU
2
Author Information
1. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
2. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. houwei1964@163.com.
- Publication Type:Review
- Keywords:
Chinese medicine;
clinical study;
evidence map;
evidence visualization;
lung cancer
- MeSH:
Drugs, Chinese Herbal/adverse effects*;
Humans;
Lung Neoplasms/drug therapy*;
Quality of Life;
Randomized Controlled Trials as Topic;
Systematic Reviews as Topic
- From:
Chinese journal of integrative medicine
2022;28(10):930-938
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:Through showing the full picture of double-arm controlled clinical research and systematic review evidence in the field of orally administrated Chinese herbal medicine (CHM) for treatment of lung cancer, to provide a reference for future clinical research and to indicate a direction for future systematic reviews.
METHODS:A comprehensive search of clinical controlled studies was performed regarding orally administered CHM treatment for lung cancer published from January 1970 to September 2020. The language was restricted to Chinese and English. Relevant data were extracted, the quality of systematic reviews was evaluated, and the research evidence was visually displayed.
RESULTS:Randomized controlled trials were the most common type of research design. The research sample sizes were typically small. Oral CHM showed certain curative advantages in treating lung cancer. The key stages in oral CHM intervention for lung cancer are chemotherapy, radiotherapy, and late palliative treatment. The advantageous outcomes of oral CHM treatment of lung cancer are the short-term efficacy, quality of life, and adverse reactions. The perioperative stage, overall survival, pharmacoeconomic evaluation, and Chinese medicine decoctions are weak research areas.
CONCLUSIONS:CHM has staged and therapeutic advantages in treating lung cancer. The overall methodological quality is poor, and the level of evidence requires improvement. It is necessary to carry out large-scale, standardized, and higher-quality research in the superior and weak areas of CHM treatment of lung cancer.
